Literature DB >> 22982990

Cross-neutralization of influenza A viruses mediated by a single antibody loop.

Damian C Ekiert1, Arun K Kashyap, John Steel, Adam Rubrum, Gira Bhabha, Reza Khayat, Jeong Hyun Lee, Michael A Dillon, Ryann E O'Neil, Aleksandr M Faynboym, Michael Horowitz, Lawrence Horowitz, Andrew B Ward, Peter Palese, Richard Webby, Richard A Lerner, Ramesh R Bhatt, Ian A Wilson.   

Abstract

Immune recognition of protein antigens relies on the combined interaction of multiple antibody loops, which provide a fairly large footprint and constrain the size and shape of protein surfaces that can be targeted. Single protein loops can mediate extremely high-affinity binding, but it is unclear whether such a mechanism is available to antibodies. Here we report the isolation and characterization of an antibody called C05, which neutralizes strains from multiple subtypes of influenza A virus, including H1, H2 and H3. X-ray and electron microscopy structures show that C05 recognizes conserved elements of the receptor-binding site on the haemagglutinin surface glycoprotein. Recognition of the haemagglutinin receptor-binding site is dominated by a single heavy-chain complementarity-determining region 3 loop, with minor contacts from heavy-chain complementarity-determining region 1, and is sufficient to achieve nanomolar binding with a minimal footprint. Thus, binding predominantly with a single loop can allow antibodies to target small, conserved functional sites on otherwise hypervariable antigens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982990      PMCID: PMC3538848          DOI: 10.1038/nature11414

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  50 in total

1.  Accurate determination of local defocus and specimen tilt in electron microscopy.

Authors:  Joseph A Mindell; Nikolaus Grigorieff
Journal:  J Struct Biol       Date:  2003-06       Impact factor: 2.867

2.  Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.

Authors:  Hing-Ken Lee; Christopher N Scanlan; Cheng-Yuan Huang; Aileen Y Chang; Daniel A Calarese; Raymond A Dwek; Pauline M Rudd; Dennis R Burton; Ian A Wilson; Chi-Huey Wong
Journal:  Angew Chem Int Ed Engl       Date:  2004-02-13       Impact factor: 15.336

3.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

4.  The influenza virus resource at the National Center for Biotechnology Information.

Authors:  Yiming Bao; Pavel Bolotov; Dmitry Dernovoy; Boris Kiryutin; Leonid Zaslavsky; Tatiana Tatusova; Jim Ostell; David Lipman
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

5.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

7.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  The biotin repressor: modulation of allostery by corepressor analogs.

Authors:  Patrick H Brown; John E Cronan; Morten Grøtli; Dorothy Beckett
Journal:  J Mol Biol       Date:  2004-04-02       Impact factor: 5.469

10.  An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody.

Authors:  Jens C Krause; Damian C Ekiert; Terrence M Tumpey; Patricia B Smith; Ian A Wilson; James E Crowe
Journal:  MBio       Date:  2011-02-08       Impact factor: 7.867

View more
  237 in total

1.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

2.  Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses.

Authors:  Natalie J Thornburg; David P Nannemann; David L Blum; Jessica A Belser; Terrence M Tumpey; Shyam Deshpande; Gloria A Fritz; Gopal Sapparapu; Jens C Krause; Jeong Hyun Lee; Andrew B Ward; David E Lee; Sheng Li; Katie L Winarski; Benjamin W Spiller; Jens Meiler; James E Crowe
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site.

Authors:  Minsun Hong; Peter S Lee; Ryan M B Hoffman; Xueyong Zhu; Jens C Krause; Nick S Laursen; Sung-Il Yoon; Langzhou Song; Lynda Tussey; James E Crowe; Andrew B Ward; Ian A Wilson
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9.

Authors:  Cong Chen; Liguo Liu; Yan Xiao; Sheng Cui; Jianmin Wang; Qi Jin
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

Review 5.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

Review 6.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

7.  Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies.

Authors:  Robyn L Stanfield; Ian A Wilson; Vaughn V Smider
Journal:  Sci Immunol       Date:  2016-07-14

8.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

Review 9.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

Review 10.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.